HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Descamps, G. Articles by Amiot, M. Search for Related Content PubMed PubMed Citation Articles by Descamps, G. Articles by Amiot, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Multiple Myeloma

The Magnitude of Akt/Phosphatidylinositol 3'-Kinase Proliferating Signaling Is Related to CD45 Expression in Human Myeloma Cells¹

Géraldine Descamps^*, Catherine Pellat-Deceunynck^*, Yann Szpak^*, Régis Bataille^*, Nelly Robillard and Martine Amiot^2,*

^* Institut National de la Santé et de la Recherche Médicale Unité 601, Ligue Nationale contre le Cancer Label, and Laboratoire d’Hématologie, Institut de Biologie, Nantes, France

In multiple myeloma, the Akt/PI3K pathway is involved in the proliferation of myeloma cells. In the current study, we have investigated the impact of the CD45 phosphatase in the control of Akt/PI3K activation. We show that Akt activation in response to insulin-like growth factor-1 (IGF-1) is highly variable from one human myeloma cell line to another one. Actually, Akt activation is highly related to whether CD45 is expressed or not. Indeed, both the magnitude and the duration of Akt phosphorylation in response to IGF-1 are more important in CD45^– than in CD45⁺ myeloma cell lines. We next demonstrate a physical association between CD45 and IGF-1 receptor (IGF-1R) suggesting that CD45 could be involved in the dephosphorylation of the IGF-1R. Furthermore, the growth of CD45^– myeloma cell lines is mainly or even totally controlled by the PI3K pathway whereas that of CD45⁺ myeloma cell lines is modestly controlled by it. Indeed, wortmannin, a specific PI3K inhibitor, induced a dramatic growth inhibition in the CD45^– myeloma cell lines characterized by a G₁ growth arrest, whereas it has almost no effect on CD45⁺ myeloma cell lines. Altogether, these results suggest that CD45 negatively regulates IGF-1-dependent activation of PI3K. Thus, strategies that block IGF-1R signaling and consequently the Akt/PI3K pathway could be a priority in the treatment of patients with multiple myeloma, especially those lacking CD45 expression that have a very poor clinical outcome.

This article has been cited by other articles:

				P. Sabbatini, J. L. Rowand, A. Groy, S. Korenchuk, Q. Liu, C. Atkins, M. Dumble, J. Yang, K. Anderson, B. J. Wilson, et al. Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase Clin. Cancer Res., May 1, 2009; 15(9): 3058 - 3067. [Abstract] [Full Text] [PDF]

				E. Menoret, S. Maiga, G. Descamps, C. Pellat-Deceunynck, C. Fraslon, M. Cappellano, P. Moreau, R. Bataille, and M. Amiot IL-21 Stimulates Human Myeloma Cell Growth through an Autocrine IGF-1 Loop J. Immunol., November 15, 2008; 181(10): 6837 - 6842. [Abstract] [Full Text] [PDF]

				M. Q. Lacy, M. Alsina, R. Fonseca, M. L. Paccagnella, C. L. Melvin, D. Yin, A. Sharma, M. Enriquez Sarano, M. Pollak, S. Jagannath, et al. Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma J. Clin. Oncol., July 1, 2008; 26(19): 3196 - 3203. [Abstract] [Full Text] [PDF]

				H. Younes, X. Leleu, E. Hatjiharissi, A.-S. Moreau, T. Hideshima, P. Richardson, K. C. Anderson, and I. M. Ghobrial Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma Clin. Cancer Res., July 1, 2007; 13(13): 3771 - 3775. [Abstract] [Full Text] [PDF]

				L. K. Francis, Y. Alsayed, X. Leleu, X. Jia, U. K. Singha, J. Anderson, M. Timm, H. Ngo, G. Lu, A. Huston, et al. Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma. Clin. Cancer Res., November 15, 2006; 12(22): 6826 - 6835. [Abstract] [Full Text] [PDF]

				G. Descamps, S. Wuilleme-Toumi, V. Trichet, C. Venot, L. Debussche, T. Hercend, M. Collette, N. Robillard, R. Bataille, and M. Amiot CD45neg but Not CD45pos Human Myeloma Cells Are Sensitive to the Inhibition of IGF-1 Signaling by a Murine Anti-IGF-1R Monoclonal Antibody, mAVE1642 J. Immunol., September 15, 2006; 177(6): 4218 - 4223. [Abstract] [Full Text] [PDF]

				A. R. Anand and R. K. Ganju HIV-1 gp120-mediated Apoptosis of T Cells Is Regulated by the Membrane Tyrosine Phosphatase CD45 J. Biol. Chem., May 5, 2006; 281(18): 12289 - 12299. [Abstract] [Full Text] [PDF]